50615-65-1

Usage

Uses

Used in Pharmaceutical Industry:
(4-Amino-2-oxo-2H-pyrimidin-1-yl)-acetic acid is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique structure and properties allow it to be incorporated into the development of new medications, potentially leading to the discovery of novel therapeutic agents.
Used in Chemical Industry:
As a building block for other chemical compounds, (4-Amino-2-oxo-2H-pyrimidin-1-yl)-acetic acid is utilized in the chemical industry for the creation of a wide range of products. Its versatility and reactivity contribute to the synthesis of various organic compounds, expanding the scope of chemical research and development.
Used in Organic Chemistry Research and Development:
(4-Amino-2-oxo-2H-pyrimidin-1-yl)-acetic acid plays a significant role in the field of organic chemistry, particularly in drug discovery. Its unique properties and structure make it an important subject of study for researchers, who are continually exploring its potential applications and interactions with other compounds to develop new and innovative pharmaceuticals.

Upstream product

• 186046-91-3 methyl (cytosine-1-yl)acetate 
• 71-30-7 Cytosine 
• 105-36-2 ethyl bromoacetate 

Relevant academic research and scientific papers

Screening of Minimalist Noncanonical Sites in Duplex DNA and RNA Reveals Context and Motif-Selective Binding by Fluorogenic Base Probes

We hypothesize that programmable hybridization to noncanonical nucleic acid motifs may be achieved by macromolecular display of binders to individual noncanonical pairs (NCPs). As each recognition element may individually have weak binding to an NCP, we d

Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants

Introducing pyrimidine bases, the basic components of nucleic acid, to P2 ligands might enhance the potency of Human Immunodeficiency Virus-1 (HIV-1) protease inhibitors because of the carbonyl and amino groups promoting the formation of extensive hydrogen bonding interactions. In this work, we provide evidence that inhibitor 10e, with N-2-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl) acetamide as the P2 ligand and a 4-methoxylphenylsulfonamide as the P2′ ligand, displayed remarkable enzyme inhibitory and antiviral activity, with the IC50 2.53 nM in vitro and a promising inhibition ratio with 68% against wild-type HIV-1 in vivo, with low cytotoxicity. This inhibitor also exhibited appreciable antiviral activity against DRV-resistant HIV-1 variants, which was of great value for further study.